1 Evaluating multiple next-generation sequencing derived tumor features to accurately

2 predict DNA mismatch repair status

- 3 Romy Walker^{1,2}, Peter Georgeson^{1,2}, Khalid Mahmood^{1,2,3}, Jihoon E. Joo^{1,2}, Enes Makalic⁴, Mark
- 4 Clendenning^{1,2}, Julia Como^{1,2}, Susan Preston^{1,2}, Sharelle Joseland^{1,2}, Bernard J. Pope^{1,3}, Ryan
- 5 Hutchinson^{1,2}, Kais Kasem⁵, Michael D. Walsh⁶, Finlay A. Macrae^{7,8}, Aung K. Win^{2,4}, John L.
- 6 Hopper⁴, Dmitri Mouradov^{9,10}, Peter Gibbs^{9,10,11}, Oliver M. Sieber^{9,10,12,13}, Dylan E.
- 7 O'Sullivan^{14,15}, Darren R. Brenner^{14,15,16}, Steven Gallinger^{17,18,19}, Mark A. Jenkins^{2,4}, Christophe
- 8 Rosty^{1,2,20,21}, Ingrid M. Winship^{7,22}, Daniel D. Buchanan^{1,2,7#}
- 9
- 10 ¹Colorectal Oncogenomics Group, Department of Clinical Pathology, Victorian Comprehensive
- 11 Cancer Centre, The University of Melbourne, Parkville, Victoria, Australia
- ¹² ² University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre,
- 13 Parkville, Victoria, Australia
- ³ Melbourne Bioinformatics, The University of Melbourne, Melbourne, Victoria, Australia
- ⁴ Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health,
- 16 The University of Melbourne, Carlton, Victoria, Australia
- ⁵ Department of Clinical Pathology, Medicine Dentistry and Health Sciences, The University of
- 18 Melbourne, Parkville, Victoria, Australia
- 19⁶ Sullivan Nicolaides Pathology, Bowen Hills, Queensland, Australia
- ⁷Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Melbourne,
- 21 Victoria, Australia
- ⁸ Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Parkville, Victoria,
- 23 Australia

- ⁹ Personalized Oncology Division, The Walter and Eliza Hall Institute of Medial Research,
- 25 Parkville, Victoria, Australia
- ¹⁰ Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia
- 27 ¹¹ Department of Medical Oncology, Western Health, Victoria, Australia
- ¹² Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia
- ¹³ Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria,
- 30 Australia
- 31 ¹⁴ Department of Oncology, University of Calgary, Calgary, Canada
- 32 ¹⁵ Department of Community Health Sciences, University of Calgary, Calgary, Canada
- ¹⁶ Department of Cancer Epidemiology and Prevention Research, Alberta Health Services,
- 34 Calgary, Canada
- 35 ¹⁷ Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- ¹⁸ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto,
- 37 Ontario, Canada
- 38 ¹⁹ Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto,
- 39 Toronto, Ontario, Canada
- 40 ²⁰ Envoi Specialist Pathologists, Brisbane, Australia
- 41 ²¹ University of Queensland, Brisbane, Australia
- 42 ²² Department of Medicine, The University of Melbourne, Parkville, Australia

- 44
- 45 Running Title: NGS tumor mismatch-repair deficiency
- 46

- 47 [#]To whom correspondence should be addressed:
- 48
- 49 Associate Professor Daniel D. Buchanan
- 50 Head, Colorectal Oncogenomics Group
- 51 Department of Clinical Pathology
- 52 The University of Melbourne
- 53 Victorian Comprehensive Cancer Centre
- 54 305 Grattan Street
- 55 Parkville, Victoria, 3010 Australia
- 56 Ph: +61 385597004
- 57 Email: <u>daniel.buchanan@unimelb.edu.au</u>
- 58
- 59
- 60
- 61 Number of text pages: 53 pages
- 62 **Figures & Tables:** 4 figures and 4 tables
- 63 **Running head:** 41 (with characters)
- 64 Abstract: 220 words
- 65 **References:** 76 references

67 Abstract

Identifying tumor DNA mismatch repair deficiency (dMMR) is important for precision medicine. 68 We assessed tumor features, individually and in combination, in whole-exome sequenced (WES) 69 70 colorectal cancers (CRCs) and in panel sequenced CRCs, endometrial cancers (ECs) and 71 sebaceous skin tumors (SSTs) for their accuracy in detecting dMMR. CRCs (n=300) with WES, 72 where MMR status was determined by immunohistochemistry, were assessed for microsatellite 73 instability (MSMuTect, MANTIS, MSIseq, MSISensor), COSMIC tumor mutational signatures 74 (TMS) and somatic mutation counts. A 10-fold cross-validation approach (100 repeats) evaluated 75 the dMMR prediction accuracy for 1) individual features, 2) Lasso statistical model and 3) an additive feature combination approach. Panel sequenced tumors (29 CRCs, 22 ECs, 20 SSTs) were 76 77 assessed for the top performing dMMR predicting features/models using these three approaches. 78 For WES CRCs, 10 features provided >80% dMMR prediction accuracy, with MSMuTect, 79 MSIseq, and MANTIS achieving >99% accuracy. The Lasso model achieved 98.3%. The additive 80 feature approach with \geq 3/6 of MSMuTect, MANTIS, MSIseq, MSISensor, INDEL count or TMS 81 ID2+ID7 achieved 99.7% accuracy. For the panel sequenced tumors, the additive feature 82 combination approach of \geq 3/6 achieved accuracies of 100%, 95.5% and 100%, for CRCs, ECs, 83 and SSTs, respectively. The microsatellite instability calling tools performed well in WES CRCs, 84 however, an approach combining tumor features may improve dMMR prediction in both WES and 85 panel sequenced data across tissue types.

86

Keywords: Colorectal cancer, DNA mismatch repair deficiency, endometrial cancer, Lynch
syndrome, microsatellite instability, *MLH1* promoter methylation, sebaceous skin tumor, tumor
mutation burden, tumor mutational signatures

90

91 **Declared conflicts of interest**

92 The authors have no conflicts of interest to declare.

93

94 Data availability statement: The datasets generated during and/or analyzed during the current
95 study are available from the corresponding author on reasonable request.

96

97 Funding

98 Funding by a National Health and Medical Research Council of Australia (NHMRC) project grant 99 GNT1125269 (PI- Daniel Buchanan), supported the design, analysis, and interpretation of data. 100 RW is supported by the Margaret and Irene Stewardson Fund Scholarship and by the Melbourne 101 Research Scholarship. DDB is supported by an NHMRC Investigator grant (GNT1194896) and 102 University of Melbourne Dame Kate Campbell Fellowship. PG is supported by the University of 103 Melbourne Research Scholarship. MAJ is supported by an NHMRC Investigator grant 104 (GNT1195099). AKW is supported by an NHMRC Investigator grant (GNT1194392). JLH is 105 supported by the University of Melbourne Dame Kate Campbell Fellowship. OMS is supported 106 by an NHMRC Senior Research Fellowship (GNT1136119). DEO is supported by a Canadian 107 Institutes of Health Research (CIHR) Post-doctoral Fellowship. BP is supported by a Victorian 108 Health and Medical Research Fellowship from the Victorian Government.

110 Introduction

111 DNA mismatch-repair (MMR) deficiency (dMMR) is an important molecular phenotype of 112 solid tumors characterized by the presence of microsatellite instability (MSI) and/or loss of 113 expression of one or more of the DNA MMR proteins, MLH1, MSH2, MSH6 and PMS2. 114 Identifying dMMR tumors is important for understanding disease prognosis¹, response to immune 115 checkpoint inhibition therapy² and to identify people with Lynch syndrome. Lynch syndrome is 116 the most common inherited cancer predisposition disorder and, therefore, the Evaluation of 117 Genomic Applications in Practice and Prevention Working Group recommends that all newly 118 diagnosed colorectal (CRC) and endometrial cancers (EC) are screened for dMMR to improve the 119 identification of carriers^{3,4}.

120 The dMMR mutator phenotype arises in tumors where errors occur during the DNA 121 replication process⁵. Specifically, defects in the components of the MMR system responsible for 122 the recognition of mismatches such as single nucleotide variants (SNVs) and insertion-deletions 123 (INDELs), can lead to the development of numerous frameshift mutations in coding and non-124 coding microsatellite regions⁶. dMMR is related to biallelic inactivation of one of the MMR genes, 125 resulting from either somatic methylation of the *MLH1* gene promoter region⁷ or double somatic MMR gene mutations⁸ (sporadic dMMR), or germline pathogenic variants in the MMR genes⁹ or 126 127 deletions in the 3' end of the EPCAM gene¹⁰ (inherited dMMR). CRC, EC and sebaceous skin 128 tumors (SSTs), including sebaceous adenomas, carcinomas and sebaceomas, are tissue types that 129 demonstrate the highest frequencies of dMMR where up to 26%¹¹, 31%¹¹ and 31%¹² of these tissue 130 types, respectively, present with the dMMR phenotype, followed by stomach cancer at 19%¹¹. 131 The most common approach for identifying dMMR tumors is by assessing MMR protein

132 expression through immunohistochemistry (MMR IHC)^{13,14} and/or by testing for high levels of

133 microsatellite instability using polymerase chain reactions (MSI-PCR)¹⁵. While both screening 134 methodologies are commonly used, each present advantages and limitations. The advantages of 135 performing MMR IHC include simple experimental execution, short turnaround time, low 136 associated costs as well as giving an indication of the defective gene¹⁶. However, false positive or 137 false negative MMR IHC results can occur due to technical artefacts, variable performance of 138 different MMR antibodies and inherent variability in the interpretation of the staining by different 139 pathologists¹⁶. Further challenges include the interpretation of weaker staining in less proliferative 140 tissue and heterogenous patterns of MMR protein loss^{17–24}.

141 While MMR IHC is more widely adopted in the clinical setting, MSI-PCR remains the gold 142 standard for detecting dMMR¹⁶; to date multiple markers have been identified to call MSI in tumor 143 samples²⁵. The limitations for MSI-PCRs include additional laboratory implementation 144 requirements related to tissue DNA extraction and increased labor costs; both can lead to a delay in receiving test results¹⁶. Nonetheless, MMR IHC and MSI-PCR methodologies have proven to 145 be effective for identifying dMMR in CRC samples²⁶ with a reported concordance of 91.9%¹⁶, but 146 147 the accuracy for either of these tools can decrease when applied to different tissue types²⁷. As next-148 generation sequencing (NGS) becomes more widely adopted for precision oncology, there is an 149 increasing need to accurately determine tumor MMR status using NGS data.

To date, several tools have been developed to assess MSI from NGS data, including MSISensor²⁸, MSIseq²⁹, MANTIS³⁰ and more recently MSMuTect³¹. To the best of our knowledge, the comparison of these four MSI tools on the same tumors has not yet been performed. In addition to MSI, other tumor features derived from NGS have been shown to be associated with dMMR, such as tumor mutational burden (TMB)³² and tumor mutational signatures (TMS)³³.

TMB, characterized by high SNV and INDEL counts, is a biomarker for response to immune
 checkpoint inhibition therapy^{34,35} and is increased in dMMR tumors³⁶.

157 TMS aggregate tens to thousands of the observed somatic mutations within a tumor into 158 patterns related to the underlying mutational processes^{37,38}. The predominant TMS framework, 159 published on the COSMIC website, defines 107 different signature definitions categorized into 160 three distinct subgroups: 1) 78 single base substitutions (SBS) where seven of the SBS signatures 161 (SBS6, SBS14, SBS15, SBS20, SBS21, SBS26 and SBS44) are associated with dMMR; 2) 18 162 small (1 to 50 base pair) insertions and deletions or ID signatures where ID1, ID2, and ID7 are 163 associated with dMMR, and 3) 11 doublet base substitutions or DBS signatures where DBS7 and 164 DBS10 have both been previously associated with dMMR³³. However, DBS signatures have a 165 reported low prevalence in CRC compared with other tissue types so were excluded from our 166 study³⁸. Previously, we have shown that the combination of individual TMS can improve the 167 ability of TMS to discriminate important molecular and genetic subtypes of CRC, including 168 identifying germline biallelic carriers of pathogenic variants in the MUTYH gene by combining SBS18 and SBS36^{39,40}. We further observed that the combination of ID2 with ID7 (TMS ID2+ID7) 169 170 was the most informative for differentiating dMMR from pMMR CRCs amongst all possible TMS 171 combinations³⁹. To date, the comparison of MSI calling tools, somatic mutation counts, TMB and 172 TMS tumor features for determining the dMMR status in CRC tumors has not yet been undertaken. 173 In this study, we assessed 104 tumor features derived from whole-exome sequencing 174 (WES) (Table 1), consisting of the MSI prediction tools (MSMuTect, MANTIS, MSIseq and 175 MSISensor), TMS (78 SBS and 18 ID signatures), TMS ID2+ID7, TMB and individual SNV and 176 INDEL somatic mutation counts for their accuracy in predicting dMMR status in 300 well-177 characterized CRCs. Secondly, we investigated whether a combination of these tumor features,

178	using either a statistical model or a simple approach that added individual features together
179	(additive feature combination), could improve the dMMR prediction accuracy in WES CRC
180	tumors. Finally, we evaluated the effectiveness of the top performing tumor features from the WES
181	analysis, individually and in combination, in an independent set of CRC, EC and SST tumors that
182	had undergone targeted multigene panel sequencing for their dMMR prediction accuracy.

183

184 Materials and Methods

185

186 Study Cohort

The study population included men and women retrospectively identified from five studies where pMMR or dMMR status was determined by MMR IHC and where an etiology for dMMR status could be defined, namely a sporadic etiology caused by tumor *MLH1* methylation or double somatic MMR mutations, or an inherited etiology caused by a germline MMR gene pathogenic variant (Lynch syndrome). The breakdown of participants included in this study by their dMMR and pMMR status, tissue type and by WES or panel sequencing is shown in **Figure 1**:

193 1) the ANGELS study (<u>Applying Novel Genomic approaches to Early-onset and suspected Lynch</u>

194 <u>Syndrome colorectal and endometrial cancers</u>)³⁹ recruited participants that were diagnosed with

195 CRC or EC between 2014 – 2021 who were referred from family cancer clinics across Australia

196 (n=79). All ANGELS study participants provided informed consent and the study was approved

197 by the University of Melbourne human research ethics committee (HREC#1750748) and

- 198 institutional review boards at each family cancer clinic;
- 199 2) CRC- or EC-affected participants from the ACCFR (<u>Australasian Colorectal Cancer Family</u>
- 200 <u>*Registry*</u>) were selected from both population-based and clinic-based recruitment (n=139);

3) CRC-affected participants from the OFCCR (<u>Ontario Familial Colorectal Cancer Registry</u>) were population-based patients (<50 years old) recruited from the Cancer Care Ontario, Toronto, Canada (n=53). Study participants from both the ACCFR and OFCCR were recruited between 1998 and 2008, and were included according to the recruitment policy and eligibility criteria previously described^{41,42}. Informed consent was obtained from all study participants and the study protocol was approved by the institutional human ethics committee at both study sites;

4) CRC-affected participants from the WEHI study (<u>Walter and Eliza Hall Institute of Medical</u>

208 *Research*) were recruited from the Royal Melbourne Hospital (Parkville, VIC, Australia) and the

209 Western Hospital Footscray (Footscray, VIC, Australia), between Jan 1, 1993, and Dec 31, 2009³⁹.

210 All patients provided written informed consent. The study was approved by human research ethics

211 committees at both sites (HREC 12/19) (n = 80);

5) SST-affected participants from the MTS study (*Muir-Torre Syndrome Study*) were referred between July 2016 and September 2021 following clinical diagnostic MMR IHC testing by Sullivan Nicolaides Pathology service in Brisbane¹² or by family cancer clinics in Australia. Informed consent was obtained from the study participants and the study protocol was approved by the human research ethics committee from the University of Melbourne (HREC#1648355) and by the relevant institutional human ethics committees (n = 20).

218

219 Tumor Categorization

MMR IHC testing was performed on formalin-fixed paraffin embedded (FFPE) tissues for all four MMR proteins for the ACCFR and OFCCR as previously described^{42–44}, and a subset of these tumors also underwent MSI-PCR testing as previously described⁴⁵. MMR IHC testing for the ANGELS and MTS studies was part of routine clinical assessment in pathology laboratories

224 across Australia, reported by the duty pathologist. Fresh-frozen tissue specimens from the WEHI 225 study were assessed for MLH1, MSH2 and MSH6 MMR IHC and MSI-PCR tested using BAT25, 226 BAT26, D5S346, D2S123 and D17S250 MSI markers. Germline MMR gene testing (as described 227 in Buchanan et al.⁴³) and tumor MLH1 promoter methylation testing by MethyLight (as described 228 in Buchanan et al.⁴⁶) were performed on all dMMR tumors showing loss of MLH1/PMS2 protein 229 expression or sole PMS2 loss by IHC. Tumors were considered to have double somatic MMR 230 mutations when they were found to have two pathogenic/likely pathogenic somatic mutations or a 231 single somatic pathogenic/likely pathogenic mutation in combination with presence of loss of 232 heterozygosity. Germline pathogenic variants and somatic MMR gene mutations were confirmed 233 in WES and targeted panel sequencing data prior to analysis. Therefore, for each of the dMMR 234 tumors included in this study we could confirm an inherited or acquired cause for their respective 235 pattern of MMR IHC protein loss. Concurrently, for the pMMR tumors, we did not find evidence 236 of a germline MMR pathogenic variant or double MMR somatic mutation in these tumor samples. 237 All tumors in the study were assigned to one of four categories based on dMMR or pMMR 238 status determined from MMR IHC and/or MSI-PCR and based on the cause for dMMR:

1) dMMR-Lynch syndrome (dMMR-LS) – identified carrier of a germline pathogenic variant
in one of the DNA MMR genes where the corresponding tumor showed commensurate loss of
MMR protein expression by IHC;

242 2) dMMR-*MLH1* methylation (dMMR-MLH1me) – tumors were positive for methylation of
243 the *MLH1* gene promoter "C region"⁴⁷ and showed loss of MLH1 and PMS2 protein expression
244 by IHC without a germline MMR gene pathogenic variant;

245 3) dMMR-double somatic (dMMR-DS) – tumors harbored two somatic mutations (SNVs and/or 246 loss of heterozygosity) in the same MMR gene that showed loss of protein expression by IHC with 247 no identified pathogenic germline MMR gene variant; and 248 4) MMR-proficient (pMMR) – tumors showed normal expression of all four MMR proteins and 249 did not show presence of double somatic MMR gene mutations or a germline MMR gene 250 pathogenic variant. 251 The three dMMR subtypes dMMR-LS, dMMR-DS and dMMR-MLH1me were combined as a 252 single dMMR tumor group in downstream analysis. 253 254 Whole-Exome and Targeted Panel Sequencing Capture Regions

The targeted panel was based on the design described in Zaidi et al.⁴⁸ consisting of probes 255 targeting the following regions: 1) 298 genes incorporating key hereditary CRC^{49-51} and EC^{52} risk 256 257 genes and genes that are frequently mutated as identified by The Cancer Genome Atlas (TCGA) 258 data^{32,53,54}, 2) 28 microsatellite loci including the five 'gold standard' MSI markers (BAT25, 259 BAT26, NR-21, NR-24, and MONO-27) currently implemented in routine MSI-PCR diagnostics, 260 3) 212 homopolymer regions distributed genome-wide to assess for MSI in tumor samples and 4) 261 56 copy number variants known to be susceptible to copy number changes in CRCs. The panel 262 capture was 2.005 megabases (Mb) in size. The WES capture incorporates all exonic regions 263 within the genome and is 67.296 Mb in size. The panel additionally included capture of intronic 264 regions within the MMR genes, which the WES capture did not cover.

265 Next-Generation Sequencing

In total, 300 CRC tumors were sequenced by WES and 71 tumors (29 CRCs, 22 ECs and 20 SSTs) were sequenced by the targeted multigene panel (**Figure 1**). FFPE CRC, EC or SST tissues were macrodissected and DNA extracted using the QIAmp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Peripheral blood-derived DNA was extracted using the DNeasy blood and tissue kit (Qiagen, Hilden, Germany) and sequenced as germline references.

272 The WES capture was the Agilent Clinical Research Exome V2 kit (Agilent Technologies 273 Santa Clara, United States) with sequencing performed on an Illumina NovaSeq 6000 comprising 274 150 base pair (bp) paired-end reads performed at the Australian Genome Research Facility³⁹. For 275 the WEHI CRCs, exome-enrichment was performed using the TruSeq Exome Enrichment Kit 276 (Illumina, San Diego, United States) and 100 bp paired-end read sequencing performed on an Illumina HiSeq 2000 at the Australian Genome Research Facility³⁹. The on-target coverage for the 277 278 300 WES samples had a median of 323.7 for the FFPE tumor DNA samples and 137.4 for blood-279 derived DNA samples, with an interquartile range of 111.8 – 426.4 and 100.6 – 204.9, respectively. 280 Library preparation for targeted panel sequencing was performed using the SureSelectTM 281 Low Input Target Enrichment System (Agilent Technologies, Santa Clara, United States) using 282 standard protocol and sequenced on an Illumina NovaSeq 6000 comprising 150 bp paired end 283 reads performed at the Australian Genome Research Facility. The on-target coverage for the 71 284 panel sequenced samples was (median and interquartile range) 919.3 and 694.6 – 1164.9 for FFPE 285 tumor DNA samples and 160.6 and 135.8 – 178.0 for blood-derived DNA samples.

286 Bioinformatics Pipeline

287 For both WES and targeted panel sequenced samples, adapter sequences were trimmed 288 from raw FASTO files using trimmomatic 0.38⁵⁵ and aligned to the GRCh37 human reference 289 genome using Burrows-Wheeler Aligner v. 0.7.12. Germline variants, somatic variants (SNVs) 290 and somatic INDELs were called using Strelka (v. 2.9.2., Illumina) using the recommended 291 workflow⁵⁶. TMS were calculated using the pre-defined set of 78 SBS and 18 ID signatures 292 published on COSMIC as version 3.2 (COSMIC, https://cancer.sanger.ac.uk/signatures/, last 293 accessed date: June 15, 2022)³³. Variants outside the WES and panel capture regions were 294 excluded and variants with the PASS filter called from Strelka were retained. Additional variant 295 filters included were restrictions to a minimum depth of 50x for germline and tumor samples with 296 a minimum variant allele frequency of 10% as detailed previously³⁹.

297

298 Selection of Features of Interest

299 The 104 tumor features selected for analysis in this study are shown in Table 1. Several 300 tools have been developed to assess MSI from NGS data. Our analysis focused on MSMuTect³¹, MANTIS³⁰, MSIseq²⁹ and MSISensor²⁸. Tumors were classified as having high levels of MSI 301 302 (MSI-H) or as microsatellite stable (MSS). We assessed all SBS (n=78) and ID (n=18) TMS as 303 described by COSMIC³³, but the DBS TMS were excluded due to their reported low prevalence 304 in CRCs³⁸. Previously, we have shown that combining ID2 and ID7 TMS enabled detection of 305 dMMR CRCs³⁹ and, therefore, was included as a tumor feature in this study. Somatic mutation 306 counts, namely SNVs or INDELs, as well as TMB (SNV and INDEL mutation count combined / Mb) were each included, given previous associations with tumor dMMR status⁵⁷. 307

309 Feature Performance Evaluation in WES data from CRCs

310 We assessed the 104 tumor features calculated from WES from 209 pMMR CRCs and 91 311 dMMR CRCs (pMMR:dMMR ratio = 2.3:1) (Figure 1). The dMMR CRCs comprised dMMR-LS 312 tumors (n=49), dMMR-MLH1me tumors (n=26) and dMMR-DS tumors (n=16). All 300 CRCs 313 were randomly partitioned into a training set (80% of CRCs) and a test set (20% of CRCs), while 314 maintaining the same pMMR:dMMR ratio, using *caret* R package⁵⁸. We performed a 10-fold cross 315 validation approach on the training set (repeated 100x) to calculate the average classification 316 accuracy by fitting a generalized linear model and determining the error rate, specificity, 317 sensitivity, and the area under the curve (AUC) with corresponding 95% confidence intervals 318 (CIs). Based on the unequal distribution of dMMR and pMMR tumors in the WES dataset, the no 319 information rate was 69.5%, indicating that any feature with this prediction accuracy was 320 equivalent to selecting a dMMR sample by chance.

321

322 Tumor feature analysis of the WES CRC dataset comprised of three different approaches:

323 A) Individual tumor feature assessment

Each of the 104 tumor features were assessed individually and then ranked by their accuracy in identifying dMMR tumors. Individual CRC tumor features with a prediction accuracy >80% from the WES data were considered good predictors for differentiating dMMR from pMMR tumors and were included in downstream analyses.

328

B) Generation of a statistical model by combining tumor features

330 We investigated whether combining tumor features using a Lasso penalized regression model⁵⁹

331 could improve the overall dMMR prediction accuracy in CRC. Lasso enables the simultaneous

332 parameter estimation and variable selection as well as having been shown to reduce overfitting 333 when compared to conventional maximum likelihood regression models. Lasso regression has a 334 tuning parameter called lambda that controls which features are included in the regression model 335 by shrinking the coefficient or "weighting" of individual features within the model towards zero, 336 helping with the exclusion of some of the features from integration into the final model via a 337 penalization process using cross-validation.

338

339 C) Applying an additive feature combination count

Our third approach investigated combining the top ranked individual tumor features in an additive approach (additive feature combination). Specifically, the tumor features that achieved a mean prediction accuracy >95% from the WES CRC analysis (from part A), were included in this approach and added together to give an overall count. The bimodal distribution supported a majority vote decision on dMMR status.

345

Assessment of individual tumor features, the statistical model and additive feature combination approaches derived from the WES analysis on panel sequenced CRCs, ECs, and SSTs

The top individual tumor features determined from (A), best performing Lasso model (B) and the additive feature combination approach (C) were then assessed for their dMMR prediction accuracy in three independent tumor sets comprised of n=29 CRCs, n=22 ECs and n=20 SSTs tested by targeted multigene panel sequencing. The *no information rate* for features analyzed from the panel dataset was at 71.8%, indicating a prediction accuracy of this value was similar to selecting a dMMR sample by chance.

355 Statistical Analysis

356 All statistical analyses were done using the R programming language (v.4.1.0). The *tidyverse* package (v.1.3.1.)⁶⁰ was used for data import, tidying and visualization purposes and the *caret* 357 (v.6.0-9.0) package⁵⁸ was used for cross-validation. Receiving operator curves (ROC) were 358 359 generated using the *pROC* package (v.1.18.0)⁶¹, with the AUC being determined using the *cvAUC* package $(v.1.1.4)^{62}$. Statistical models were fitted using the Lasso (glmnet, v.4.1-3)^{63} package. We 360 361 used the *cutpointr* (v.1.1.1) package⁶⁴ for estimation of the best "cut points" or "thresholds" which 362 maximize the Youden-index (true positive rate minus false positive rate over all possible cut 363 points), defined as the most optimal threshold in binary disease classification tasks. Here, the 364 cutpointr package determines a recommended threshold that best differentiates dMMR from 365 pMMR cases for each feature and validates its performance using bootstrapping. The average 366 weight for each group was calculated using the *plvr* (v.1.0.7) package⁶⁵. The *ggplot2* (v.3.3.5) package⁶⁶ was used for data visualization in combination with *hrbrthemes* $(v.0.8.0)^{67}$ for histogram 367 generation and ggrepel (v.0.9.1)⁶⁸ for histogram annotations. Correlation scores between the 368 369 dMMR and pMMR groups were estimated by a *heteroscedastic two-tailed t-test*. P-values <0.05 370 were considered statistically significant. The 95% CIs for the WES data were calculated using the binomial (Clopper-Pearson) "exact" method⁶⁹ and for the targeted panel data using the binom 371 372 (v.1.1-1) package⁷⁰ in R.

373

374 **Results**

For the initial performance evaluation of 104 tumor features we assessed 209 (69.7%) pMMR
CRCs and 91 (30.3%) dMMR CRCs sequenced by WES. The clinicopathological characteristics,
pattern of MMR IHC loss and dMMR etiology are summarized in Supplementary Table 1. The

378 mean age at CRC diagnosis (\pm standard deviation, SD) for the dMMR group was 51 \pm 15.0 with 379 62.6% being female and 49 ± 16.3 with 55.5% being female for the pMMR group. The 380 clinicopathological characteristics, pattern of MMR IHC loss and dMMR etiology for panel 381 sequenced CRC (n=29), EC (n=22) and SST (n=20) tumors are summarized in Supplementary 382 **Table 2**. Within the panel sequenced tumors, the proportion of dMMR for the CRC, EC and SST 383 subsets was 72.4% (21/29), 81.8% (18/22) and 65.0% (13/20), respectively. The predominant 384 dMMR subtype across the CRC WES and targeted panel sequenced tumors was dMMR-LS 385 (53.8% and 66.7%, respectively). Within the dMMR subgroup, the most predominant pattern of 386 loss observed in CRCs and ECs was MLH1/PMS2 (WES CRCs: 65.9%, panel CRCs: 47.6% and 387 ECs: 50.0%), whereas for the SSTs tumors, this was MSH2/MSH6 loss (76.9%). Tumors showing 388 less common patterns of MMR loss including solitary loss of MSH6 or PMS2 by IHC were present 389 in both the WES CRCs (16.5%) and panel sequenced tumors (19.2%), however, sole PMS2 loss 390 cases were absent from the EC and SST cohorts.

391

392 Assessment of Tumor Features for dMMR Prediction Accuracy in WES CRCs

A) Individual tumor feature assessment

Twelve of the 104 tumor features derived from WES had a mean dMMR prediction accuracy >80% on the test dataset (**Table 2**). The mean accuracy for the remaining 92 features is shown in **Supplementary Table 3**. The four MSI tools were among the best predictors, with MSMuTect, MSIseq and MANTIS each achieving a mean prediction accuracy of \geq 99.0% with MSMuTect achieving the highest accuracy (99.3%, 95% CI: 99.1%-99.5%) (**Table 2**). The combination of TMS ID2+ID7 achieved an accuracy of 96.8% (95% CI: 96.4%-97.2%), and outperformed these signatures individually (**Table 2**). To avoid collinearity issues between the

401 combined TMS ID2+ID7 variable with the individual TMS ID2 and TMS ID7 features, the latter 402 were excluded from downstream analysis as they provided a lower prediction score. Therefore, the 403 remaining 10 features were considered as the top 10 dMMR predictors and included in subsequent 404 analyses (Figure 1).

405 The mean, SD, and range of values for each of these top 10 dMMR predictive features by 406 MMR status and by dMMR subtype for the 300 WES CRCs are shown in Supplementary Table 407 4. For each of these features, the mean values were significantly different between the dMMR and pMMR CRCs (all p<1x10⁻¹² from a *two-tailed t-test*), with TMS ID2+ID7 showing the most 408 409 significant difference (p-value = 7.775×10^{-98}), although MSISensor presented with the highest 410 Cohen's d effect size of 4.5, indicating that the means of the pMMR and dMMR groups differed 411 by more than four times the SD (Supplementary Table 4). The variation in proportion or counts 412 was larger in the dMMR tumors than in the pMMR tumors for all but one of these top 10 features 413 where TMS ID2+ID7 demonstrated a broad range of values in the pMMR CRCs compared with 414 the dMMR CRCs (Figure 2, Supplementary Table 4).

The AUCs for the top 10 features when taking all possible thresholds into account are shown in **Supplementary Figure 1.** The MSI prediction tools MSMuTect, MSIseq, and MANTIS as well as INDEL count demonstrated the best AUCs. In addition, we calculated recommended thresholds for each feature for differentiating dMMR from pMMR CRCs using the methodology described in the methods (**Supplementary Table 5**). When applying these thresholds, it was not possible to achieve a complete separation between the dMMR and pMMR tumors for each of the tumor features (**Figure 3**).

Investigation of the CRCs misclassified based on the individual tumor feature analysis
demonstrated that the misclassification rate (error rate) for the MSI tools was low with MSMuTect

424 (2/300), MANTIS (1/300), MSIseq (1/300) and MSISensor (5/300) calling \leq 5 incorrectly out of 425 300 tumors ($\leq 1.7\%$ error rate). Of the CRCs misclassified by the MSI tools, only two tumors were 426 misclassified by more than one MSI tool, both were dMMR-MLH1me CRCs classified as pMMR. 427 Of note, one of these dMMR-MLH1me CRCs was misclassified as a pMMR tumor by 9 out of the 428 top 10 tumor features. The second misclassified dMMR-MLH1me CRC was classified as pMMR 429 by MSMuTect and MSISensor but classified as dMMR by MSIseq and MANTIS (overall 6/10 430 features classified this CRC as dMMR). For INDEL count, 3/300 were incorrectly classified, 431 where two pMMR CRCs were classified as dMMR. TMS ID2+ID7 had 10/300 incorrect 432 classifications with seven pMMR tumors incorrectly called as dMMR. The remaining features 433 from the top 10 prediction accuracy list demonstrated the following incorrect classifications: 434 SBS20 (34/300), SBS54 (55/300), SBS15 (44/300) and TMB (19/300) encompassing incorrect 435 calls in both directions (dMMR to pMMR and vice versa).

436

437 B) Generation of a statistical model by combining tumor features

We assessed whether a combination of features within a statistical model could improve dMMR prediction accuracy. For this, we performed a Lasso penalized logistic regression. Here, after calculating the best lambda value, we found that the combination of TMS ID2+ID7 (coefficient = 5.29), MANTIS (coefficient = 1.70), MSISensor (coefficient = 0.09) with SBS15 (coefficient = 2.25) provided the best prediction accuracy from all possible feature combinations, demonstrating a mean accuracy of 98.3% (95% CI: 0.981-0.986), sensitivity of 0.973 (95% CI: 0.966-0.980) and specificity of 1.000 (95% CI: 1.000-1.000) on the test set.

445 *C)* Assessing an additive feature combination count for dMMR prediction

446 Based on the observation that the top performing tumor features from the individual feature 447 analysis did not all misclassify the same CRCs lead us to explore a novel approach of combining 448 tumor features together to increase the overall accuracy i.e., an additive tumor feature combination 449 approach. This approach used a majority count of individual tumor features to overcome the small 450 inaccuracies that each of the top tumor features displayed individually i.e., if one of these top 451 dMMR predictive tumor features misclassified a CRC then the other top dMMR predictive tumor 452 features would correctly classify the same CRC and, thereby, achieve the correct classification 453 overall. Six of the top 10 features from the 10-fold cross-validation analysis demonstrated a mean 454 prediction accuracy of >95% and thus had the least number of incorrect CRC tumor classifications, 455 consisting of MSMuTect, MANTIS, MSIseq, MSISensor, INDEL count, and TMS ID2+ID7. We 456 applied the recommended threshold for determining dMMR status determined previously for each 457 tumor feature (Figure 3, Supplementary Table 5) to derive a count out of these six selected 458 features, in which each feature is weighted equally. The results show a bimodal distribution across 459 the 300 CRCs (Figure 4) where 0/6 to 2/6 features correctly classified all the pMMR CRCs and 460 4/6 to 6/6 correctly classified all but one of the dMMR tumors with an accuracy of 99.7%. The 461 only exception was the previously mentioned dMMR-MLH1me tumor, which did not meet the 462 recommended thresholds for all six features and thus received a count of 0/6 features suggestive 463 the CRC is pMMR rather than its initial dMMR status.

464

465 A summary of the results from the WES CRC analysis for the three approaches is shown466 in Table 3 and Figure 1.

<u>Assessment of individual tumor features, Lasso statistical model and additive feature combination</u> approaches derived from the WES analysis on panel sequenced CRCs, ECs, and SSTs

To determine the generalizability of the findings from the three approaches performed on the WES CRCs, we tested 71 tumors with targeted panel sequencing data to evaluate performance on both a smaller capture and across different tissue types known to have a high prevalence of dMMR.

474 *A)* Evaluation of the top performing individual features from WES analysis on the panel sequenced
475 CRC, EC, and SST tumors

476 Out of the top 10 dMMR tumor features from the WES CRC analysis, only four achieved a 477 mean dMMR prediction accuracy of >80% in the panel sequenced CRC tumors (Table 4). For EC 478 and SST tumors only one feature (MANTIS) and two features (MANTIS and TMS ID2+ID7), 479 respectively, of the top 10 tumor features achieved a mean dMMR prediction accuracy of >80% 480 (Table 4). Across the three tissue types, MANTIS demonstrated the highest mean accuracy, 481 achieving 100% (95% CI: 88.1%-100.0%) accuracy in the panel sequenced CRCs, 86.4% accuracy 482 in ECs (95% CI: 65.1%-97.1%) and 85% accuracy in SSTs (95% CI: 62.1%-96.8%) (Table 4). 483 MSMuTect and INDEL count performed poorly in all three panel sequenced tissue types compared 484 with their accuracy in the WES CRCs. MSMuTect and INDEL count are features that provide 485 absolute counts that in our data were two orders of magnitude smaller in the panel sequenced 486 tumors compared with the WES CRCs. The reduction in discriminatory ability is likely related to 487 differences in the size (WES: 67.7 Mb and panel: 2.0 Mb) and location (additional coverage of 488 intronic regions of the MMR genes in the panel capture) of the regions covered by the WES and 489 panel captures resulting in a lower somatic mutation count.

490 The mean, SD, and range of values for each of these top 10 dMMR predicting features by 491 MMR status and by dMMR subtype for each of CRC, EC and SST tissue types are shown in 492 Supplementary Tables 6A, 6B, 6C and in Supplementary Figure 2, Supplementary Figure 3, 493 and Supplementary Figure 4, respectively. The mean values of each of the top 10 predictors were 494 significantly different between the dMMR and pMMR tumors in all three tissue types except for 495 TMS SBS15 in CRCs, MSISensor in ECs, TMB in ECs and SSTs and, TMS SBS20 and TMS 496 SBS54 in SSTs. MSMuTect consistently had the highest Cohen's d effect size of all top 10 tumor 497 features for each tissue type with the highest effect size observed in CRCs (3.2), indicating the 498 mean of the dMMR and pMMR subgroups for this feature differ by approximately three SDs.

499

500 B) Evaluation of the Lasso statistical model on the panel sequenced CRC, EC, and SST tumors

501 From WES analysis, the Lasso statistical model comprised of TMS ID2+ID7, MANTIS, 502 MSISensor and SBS15 achieved a mean prediction accuracy of 98.3%. When this model was 503 applied, with the coefficients determined from the WES analysis, on these three independent panel 504 sequenced tissue types, the prediction accuracies were lower (CRC: 89.7%, EC: 68.2% and SST: 505 85.0%) (**Table 3**).

506

507 *C)* Evaluation of the additive tumor feature combination approach on the panel sequenced CRC,
508 *EC*, and SST tumors

509 For each of the top 10 dMMR predictive tumor features we determined the optimal thresholds 510 for the panel sequenced CRCs, ECs, and SSTs (**Supplementary Table 5**) and plotted them by 511 tissue type (CRC - **Supplementary Figure 5**), (EC - **Supplementary Figure 6**), (SST -512 **Supplementary Figure 7**). The determined thresholds for MANTIS were consistent across both

WES and panel captures as well as across tissue types while the calculated thresholds for MSIseq were consistent for CRC across WES and panel captures but different to the thresholds determined for EC and SST. The remaining eight tumor features showed variability in their determined thresholds across both capture type and tissue type (**Supplementary Table 5**). As such, we applied the thresholds determined for each tissue type for the panel sequenced data in the additive feature combination approach below.

519

520 The additive feature combination approach incorporates a count of MSMuTect, MANTIS, 521 MSIseq, MSISensor, INDEL count and TMS ID2+ID7 tumor features to classify a tumor as 522 dMMR. The distribution of the counts of these six tumor features determined for each tumor are 523 shown for CRC (Supplementary Figure 8), EC (Supplementary Figure 9) and SSTs 524 (Supplementary Figure 10). For each tissue type, all the dMMR tumors had $\geq 3/6$ tumor features 525 classify them as dMMR, except for a single dMMR-MLH1me EC (1/71, 1.4%) which scored 0/6 526 and, therefore, was suggestive of pMMR status. This approach achieved accuracy scores of 100%, 527 95.5% and 100%, for CRC, EC and SST, respectively (Table 3).

528

A summary of the WES CRC and CRC, EC, and SST panel sequencing results for all three
approaches is provided in Table 3.

531

532 **Discussion**

In this study, we compared tumor features calculated from next generation sequencing data for their accuracy in predicting dMMR status in 300 CRCs, 91 of which were dMMR determined by immunohistochemistry or MSI-PCR and with an established sporadic or inherited etiology for

536 their dMMR status. Ten features achieved >80% dMMR prediction accuracy from the WES CRC 537 tumors, with the highest accuracy predictors being the MSI tools MSMuTect, MSIseq and 538 MANTIS, all of which achieved ≥99% accuracy. The combination of TMS ID2+ID7 achieved the 539 highest mean accuracy for dMMR prediction out of the 97 TMS features assessed. When applied 540 to the targeted multi-gene panel setting, the performance of these 10 features was reduced not only 541 in CRC but also for the EC and SST tumors. In addition, we investigated two approaches that 542 combined these top 10 performing tumor features to improve the overall prediction accuracy. The 543 Lasso generated model achieved 98.3% accuracy in WES CRCs although the performance of the 544 model was reduced in the panel sequenced CRC, EC, and SST tumors. For both the WES CRCs 545 and panel sequencing across tissue types, the additive tumor feature combination approach, where 546 having ≥ 3 of the top 6 tumor features classify a tumor as dMMR, achieved the highest prediction 547 accuracies of the three approaches tested.

548

549 To date, multiple tools to detect MSI from NGS data have been developed⁷¹. NGS based MSI 550 tool development has been constantly evolving since the introduction of MSISensor²⁸ and mSINGS⁷², which were followed by MSIseq²⁹, MANTIS³⁰ and MSMuTect³¹. However, to the best 551 552 of our knowledge, neither a comparison of more than three MSI detection tools on the same tumor 553 sample nor the effectiveness of these MSI tools specifically on SST tumors has been performed to 554 date. Previously, MANTIS has been compared to MSISensor with the former showing superior sensitivity (97.18% vs. 96.48%) and specificity (99.68% vs. 98.73%)³⁰. This was supported by our 555 556 findings, and we additionally showed that across the WES and panel tested CRCs, MANTIS 557 provided the highest dMMR prediction accuracy and was shown to be the top performing feature 558 in the EC and SST tumors as well. Recently, the United States Food and Drug Administration

(FDA) approved MSISensor for detecting MSI in metastatic CRCs for selecting patients for immune checkpoint inhibition therapy⁷³. In our study, MSISensor had the lowest accuracy (97.7%) in WES CRCs of the four MSI tools tested, incorrectly classifying 5/300 CRCs. Seeking FDA approval for other MSI tools in addition to MSISensor is warranted based on our findings.

563

564 MSMuTect has been trained on 20 different tissue types using WES data and, therefore, it 565 was not surprising it had the highest mean accuracy of the top performing tumor features in our 566 WES CRC analysis. MSMuTect has been designed to accurately detect somatic MSI indels using a count of indels from the captured sequencing region³¹. Thus, the MSI indel count from WES data 567 568 (67.7 Mb) could be up to ~34x larger than that from panel data (2.0 Mb), which likely explains the 569 poor performance of this tool observed in our panel sequencing data test sets. When we adjusted 570 the MSMuTect threshold for calling dMMR for panel data, MSMuTect showed improved 571 discrimination of dMMR from pMMR tumors. This increase in prediction accuracy was also 572 observed for the INDEL count where adjusting the threshold for panel data improved the overall 573 performance. Adjusting the threshold for panel sequencing data enabled the inclusion of 574 MSMuTect and INDEL count as two of the six tumor features in our additive feature combination 575 approach that ultimately performed well on panel sequenced tumors. Tumor features that calculate 576 a percentage rather than raw counts such as MANTIS, MSISensor, SBS TMS and ID TMS are 577 more adaptable to changes in capture size. For example, our results showed that the calculated 578 thresholds for differentiating dMMR from pMMR for MANTIS were consistent across both WES 579 and panel captures as well as across tissue types. Therefore, we recommend training features that 580 incorporate a count of genomic variants, such as INDELs, SNVs and MSMuTect on the capture 581 size to improve dMMR prediction accuracy.

582

583 While three ID TMS (ID1, ID2 and ID7) are reported to be associated with dMMR³³, our 584 results showed that the combination of ID2 and ID7 TMS achieved the highest dMMR prediction 585 accuracy of any of the TMS features in WES CRC tumors, outperforming ID2 or ID7 alone. Of 586 the seven SBS TMS that are associated with dMMR (SBS6, SBS14, SBS16, SBS20, SBS21, 587 SBS26 and SBS44)³³, only two, TMS SBS15 and TMS SBS20, showed >80% dMMR prediction 588 accuracy in WES CRC tumors, but were shown to be poor predictors in the panel sequenced 589 tumors. Interestingly, TMS SBS54 was one of the top 10 dMMR predictors from the WES CRC 590 analysis, although currently its proposed etiology in COSMIC is related to a "possible sequencing 591 artefact and/or a possible contamination with germline variants"³³. Another study has shown that 592 SBS15, SBS20 and SBS54 are observed in CRCs with a high immune cytolytic activity (CYT) 593 compared with CYT-low CRCs⁷⁴. CYT-high CRCs have been shown to correlate with an increased 594 somatic mutation load and high levels of MSI⁷⁵, this may explain the observation of TMS SBS15, 595 TMS SBS20 and TMS SBS54 demonstrating >80% dMMR prediction accuracy in our WES CRC 596 analysis.

597

The combination of tumor features via the Lasso regression model achieved similar mean accuracy as the four MSI tools individually in the WES CRC analysis. The Lasso calculated final model that best distinguished dMMR from pMMR tumors in the WES CRC cohort consisted of TMS ID2+ID7, MANTIS, MSISensor and TMS SBS15. The statistical approach used to determine the final model assigns a 'weight' (coefficient value) or confidence of how well each feature detects dMMR. As per generalized linear modelling methodology, the weight of any given feature is reduced as the model incorporates additional features. Hence, with MANTIS being one of the

best predictors, its weighting was reduced when other features were added to the final model. This resulted in the Lasso model prediction accuracy being lower than MANTIS alone. Of note, since most of the approaches taken (i.e., assessing features individually or in combination) already achieved a very high prediction accuracy of ~99%, alternate modelling approaches such as Random Forest would not result in a significant improvement in dMMR prediction accuracy.

610

611 Strengths of our study were a large sample of tumors including dMMR tumors with 612 confirmed sporadic or inherited etiology concordant with MMR IHC and MSI-PCR results for 613 both the WES and panel sequenced datasets. Tumor MMR status combined with identified 614 etiology provided a more reliable reference group of CRCs than would a group based on MMR 615 IHC test results without etiological confirmation given the known challenges that can lead to false 616 positive and negative MMR IHC results¹⁶. We assessed many tumor features that can be readily 617 derived from NGS data ensuring that our findings have potential to be easily implemented in 618 clinical diagnostics. We applied our findings from WES to panel data to determine the 619 generalizability of our findings to smaller panel captures such as those that are currently used in 620 clinical diagnostics. We showed the applicability of our findings on tissue types that display a high 621 proportion of dMMR phenotype. Our dMMR tumor samples included those with the frequent 622 pattern of MMR IHC namely MLH1/PMS2 loss and MSH2/MSH6 loss but also tumors with 623 solitary MSH6 loss or solitary PMS2 loss, ensuring we covered the spectrum of dMMR tissue 624 types which is particularly relevant given the identified challenges associated with interpretation 625 of solitary MSH6 loss⁷⁶.

627 There were several limitations of our study including testing of only three tissue types. 628 Testing of these tumor features and approaches in other tissue types such as stomach cancer, which 629 also has a high prevalence of dMMR overall and dMMR related to Lynch syndrome, would 630 determine the suitability of these tumor features for inclusion in an additive feature combination 631 approach in a pan-cancer setting. In addition, the sample size for the panel sequenced tumors was 632 limited for all three tissue types, however, there was a high proportion of dMMR in the tumors 633 tested (72.4% for CRC, 81.8% for EC and 65.0% for SST). No tumor feature or approach achieved 634 100% accuracy in the CRC WES analysis. This was largely related to a single tumor (dMMR-635 MLH1me) from the WES CRC analysis that was called incorrectly by 9/10 top individual tumor 636 features suggesting the CRC was pMMR. Therefore, we repeated the *MLH1* methylation testing 637 for this tumor using both MethyLight and MS-HRM assays. Both assays found no evidence of 638 MLH1 methylation in the tumor. These new MLH1 methylation results and the pMMR 639 classification from our analysis suggest the initial dMMR classification was a false positive. If this 640 CRC would initially have been categorized as a pMMR tumor, then MANTIS and MSIseq would 641 have achieved 100% accuracy in the WES CRC analysis. Furthermore, the identification of an 642 initial tumor misclassification provides strong support for evaluating multiple dMMR prediction 643 tumor features and highlights the advantage of combining these features through an additive 644 feature combination approach.

645

646 Conclusion

647 Our findings provide an important comparison of tumor features for dMMR prediction,
 648 highlighting performance differences between capture size and tissue types. Our results
 649 demonstrate the high accuracy of multiple individual tumor features including the MSI calling

650 tools MSMuTect, MSIseq, MANTIS and MSISensor, as well as INDEL count and the combination 651 of TMS ID2+ID7 for predicting dMMR status using WES CRCs. Moreover, our findings highlight 652 the benefit of combining these six tumor features in a simple additive feature combination 653 approach to improve dMMR prediction accuracy, particularly in targeted panel sequencing data 654 from CRC, EC, or SST tumors. With the reported inaccuracies of MMR IHC and the increasing 655 application of clinical NGS testing of tumor tissue, accurately deriving dMMR status from this 656 NGS data will have important implications for diagnostics and targeted therapy and likely improve 657 patient outcomes and cancer prevention.

658

659 Acknowledgements: We thank members of the Colorectal Oncogenomics Group and members 660 from the Genomic Medicine and Family Cancer Clinic for their support of this manuscript. We 661 thank the participants and staff from the Australasian and Ontario Colorectal Cancer Family 662 Registries (ACCFR/OFCCR) and the ANGELS, Muir-Torre and WEHI studies. We especially 663 thank Maggie Angelakos, Samantha Fox, Allyson Templeton for supporting this study. We thank 664 the Australian Genome Research Facility for their collaboration on this project. We thank A/Prof 665 Sue Finch of the Melbourne Statistical Consulting Platform and Statistical Consulting Centre at 666 the University of Melbourne for guidance with the statistical aspects of this study.

667 **References**

- 1. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S.
- 669 Tumor microsatellite instability and clinical outcome in young patients with colorectal
- 670 cancer. N Engl J Med, 2000, 342:69–77
- 2. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS,
- 672 Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee
- JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban
- 674 RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC,
- Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. PD-1 Blockade in Tumors
- with Mismatch-Repair Deficiency. N Engl J Med, 2015, 372:2509–20
- 677 3. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
- 678 Recommendations from the EGAPP Working Group: genetic testing strategies in newly
- 679 diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from
- 680 Lynch syndrome in relatives. Genet Med, 2009, 11:35–41
- 681 4. Green RF, Ari M, Kolor K, Dotson WD, Bowen S, Habarta N, Rodriguez JL, Richardson
- 682 LC, Khoury MJ. Evaluating the role of public health in implementation of genomics-related
- 683 recommendations: a case study of hereditary cancers using the CDC Science Impact
- 684 Framework. Genet Med, 2019, 21:28–37
- 5. Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacol Ther, 2018, 189:45–62
- 686 6. Eshleman JR, Markowitz SD. Mismatch repair defects in human carcinogenesis. Hum Mol
 687 Genet, 1996, 5 Spec No:1489–94
- 688 7. Young J, Simms LA, Biden KG, Wynter C, Whitehall V, Karamatic R, George J, Goldblatt
- J, Walpole I, Robin S-A, Borten MM, Stitz R, Searle J, McKeone D, Fraser L, Purdie DR,

- 690 Podger K, Price R, Buttenshaw R, Walsh MD, Barker M, Leggett BA, Jass JR. Features of
- 691 Colorectal Cancers with High-Level Microsatellite Instability Occurring in Familial and
- 692 Sporadic Settings. Am J Pathol, 2001, 159:2107–16
- 693 8. Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, de la Chapelle A, Pritchard
- 694 CC. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic,
- rather than germline, mutations. Gastroenterology, 2014, 147:1308-1316.e1
- 696 9. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch
- 697 syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal
- ramifications. Clin Genet, 2009, 76:1–18
- 699 10. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY,
- 700 Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van
- 701 Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N. Heritable somatic
- methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of
- 703 the 3' exons of TACSTD1. Nat Genet, 2009, 41:112–7
- 11. Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen H-Z, Reeser JW, Yu L,
- Roychowdhury S. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO
 Precis Oncol, 2017, 2017
- 12. Walsh MD, Jayasekara H, Huang A, Winship IM, Buchanan DD. Clinico-pathological
- 708 predictors of mismatch repair deficiency in sebaceous neoplasia: A large case series from a
- single Australian private pathology service. Australas J Dermatol, 2019, 60:126–33
- 710 13. Mascarenhas L, Shanley S, Mitchell G, Spurdle AB, Macrae F, Pachter N, Buchanan DD,
- 711 Ward RL, Fox S, Duxbury E, Driessen R, Boussioutas A. Current mismatch repair

- 712 deficiency tumor testing practices and capabilities: A survey of Australian pathology
- 713 providers. Asia Pac J Clin Oncol, 2018, 14:417–25
- 714 14. Shia J. Immunohistochemistry versus microsatellite instability testing for screening
- 715 colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome.
- Part I. The utility of immunohistochemistry. J Mol Diagn, 2008, 10:293–300
- 717 15. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ,
- 718 Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute
- 719 Workshop on Microsatellite Instability for cancer detection and familial predisposition:
- development of international criteria for the determination of microsatellite instability in
- 721 colorectal cancer. Cancer Res, 1998, 58:5248–57
- 16. Chen M-L, Chen J-Y, Hu J, Chen Q, Yu L-X, Liu B-R, Qian X-P, Yang M. Comparison of
 microsatellite status detection methods in colorectal carcinoma. Int J Clin Exp Pathol, 2018,
 11:1431–8
- 17. Chapusot C, Martin L, Bouvier AM, Bonithon-Kopp C, Ecarnot-Laubriet A, Rageot D,
- Ponnelle T, Laurent Puig P, Faivre J, Piard F. Microsatellite instability and intratumoural
 heterogeneity in 100 right-sided sporadic colon carcinomas. Br J Cancer, 2002, 87:400–4
- 18. Graham RP, Kerr SE, Butz ML, Thibodeau SN, Halling KC, Smyrk TC, Dina MA, Waugh
- 729 VM, Rumilla KM. Heterogenous MSH6 loss is a result of microsatellite instability within
- 730 MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas. Am J
- 731 Surg Pathol, 2015, 39:1370–6
- 19. Joost P, Veurink N, Holck S, Klarskov L, Bojesen A, Harbo M, Baldetorp B, Rambech E,
- 733 Nilbert M. Heterogenous mismatch-repair status in colorectal cancer. Diagn Pathol, 2014,
- 734 9:126

- 735 20. McCarthy AJ, Capo-Chichi J-M, Spence T, Grenier S, Stockley T, Kamel-Reid S, Serra S,
- 736 Sabatini P, Chetty R. Heterogenous loss of mismatch repair (MMR) protein expression: a
- challenge for immunohistochemical interpretation and microsatellite instability (MSI)
- evaluation. J Pathol Clin Res, 2019, 5:115–29
- 739 21. Pai RK, Plesec TP, Abdul-Karim FW, Yang B, Marquard J, Shadrach B, Roma AR. Abrupt
- 140 loss of MLH1 and PMS2 expression in endometrial carcinoma: molecular and morphologic
- analysis of 6 cases. Am J Surg Pathol, 2015, 39:993–9
- 742 22. Shia J, Zhang L, Shike M, Guo M, Stadler Z, Xiong X, Tang LH, Vakiani E, Katabi N,
- 743 Wang H, Bacares R, Ruggeri J, Boland CR, Ladanyi M, Klimstra DS. Secondary mutation in
- a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in

colorectal carcinomas with MLH1/PMS2 deficiency. Mod Pathol, 2013, 26:131–8

- 746 23. Watkins JC, Nucci MR, Ritterhouse LL, Howitt BE, Sholl LM. Unusual Mismatch Repair
- 747 Immunohistochemical Patterns in Endometrial Carcinoma. Am J Surg Pathol, 2016, 40:909–
- 748 16
- 749 24. Watson N, Grieu F, Morris M, Harvey J, Stewart C, Schofield L, Goldblatt J, Iacopetta B.
- 750 Heterogeneous staining for mismatch repair proteins during population-based prescreening
- 751 for hereditary nonpolyposis colorectal cancer. J Mol Diagn, 2007, 9:472–8
- 752 25. Baudrin LG, Deleuze J-F, How-Kit A. Molecular and computational methods for the
- detection of microsatellite instability in cancer. Frontiers in Oncology, 2018, 8
- 26. Vasen HFA, Hendriks Y, de Jong AE, van Puijenbroek M, Tops C, Bröcker-Vriends AHJT,
- 755 Wijnen JTh, Morreau H. Identification of HNPCC by Molecular Analysis of Colorectal and
- Endometrial Tumors. Dis Markers, 2004, 20:207–13

- 757 27. Siemanowski J, Schömig-Markiefka B, Buhl T, Haak A, Siebolts U, Dietmaier W, Arens N,
- 758 Pauly N, Ataseven B, Büttner R, Merkelbach-Bruse S. Managing Difficulties of
- 759 Microsatellite Instability Testing in Endometrial Cancer-Limitations and Advantages of Four
- 760 Different PCR-Based Approaches. Cancers (Basel), 2021, 13:1268
- 761 28. Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, Wendl MC, Ding L. MSIsensor:
- 762 microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics,
- 763 2014, 30:1015–6
- 29. Ni Huang M, McPherson JR, Cutcutache I, Teh BT, Tan P, Rozen SG. MSIseq: Software for
- Assessing Microsatellite Instability from Catalogs of Somatic Mutations. Sci Rep, 2015,
- 5:13321
- 30. Kautto EA, Bonneville R, Miya J, Yu L, Krook MA, Reeser JW, Roychowdhury S.
- 768 Performance evaluation for rapid detection of pan-cancer microsatellite instability with
- 769 MANTIS. Oncotarget, 2017, 8:7452–63
- 31. Maruvka YE, Mouw KW, Karlic R, Parasuraman P, Kamburov A, Polak P, Haradhvala NJ,
- Hess JM, Rheinbay E, Brody Y, Koren A, Braunstein LZ, D'Andrea A, Lawrence MS, Bass
- 772 A, Bernards A, Michor F, Getz G. Analysis of somatic microsatellite indels identifies driver
- events in human tumors. Nat Biotechnol, 2017, 35:951–9
- 32. Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, Kovar CL,
- 775 Lewis LR, Morgan MB, Newsham IF, Reid JG, Santibanez J, Shinbrot E, Trevino LR, Wu
- Y-Q, Wang M, Gunaratne P, Donehower LA, Creighton CJ, Wheeler DA, Gibbs RA,
- TTT Lawrence MS, Voet D, Jing R, Cibulskis K, Sivachenko A, Stojanov P, McKenna A, Lander
- ES, Gabriel S, Getz G, Ding L, Fulton RS, Koboldt DC, Wylie T, et al. Comprehensive
- molecular characterization of human colon and rectal cancer. Nature, 2012, 487:330–7

780	33. Tate JG. Bar	nford S. Jubb HC.	. Sondka Z. Beare DM	. Bindal N	Boutselakis H.	Cole CG.
100	55. Tute 50, Dui		, Domana L, Deare Di		Douboranto II,	$\cos 0.00$

- 781 Creatore C, Dawson E, Fish P, Harsha B, Hathaway C, Jupe SC, Kok CY, Noble K, Ponting
- 782 L, Ramshaw CC, Rye CE, Speedy HE, Stefancsik R, Thompson SL, Wang S, Ward S,
- 783 Campbell PJ, Forbes SA. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic
- 784 Acids Res, 2019, 47:D941–7
- 785 34. Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A,
- 786 Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB,
- 787 Bhanot G, Ganesan S. Identifying a Clinically Applicable Mutational Burden Threshold as a
- 788 Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. JCO
- 789 Precis Oncol, 2017, 2017
- 35. Zheng M. Tumor mutation burden for predicting immune checkpoint blockade response: the
 more, the better. J Immunother Cancer, 2022, 10:e003087
- 792 36. Chang H, Sasson A, Srinivasan S, Golhar R, Greenawalt DM, Geese WJ, Green G, Zerba K,
- 793 Kirov S, Szustakowski J. Bioinformatic Methods and Bridging of Assay Results for Reliable
- 794 Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer. Mol Diagn Ther,
- 795 2019, 23:507–20
- 796 37. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell
- GR, Bolli N, Borg A, Børresen-Dale A-L, Boyault S, Burkhardt B, Butler AP, Caldas C,
- Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B,
- 799 Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DTW, Jones D, Knappskog S, Kool M,
- 800 Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, et al. Signatures of
- 801 mutational processes in human cancer. Nature, 2013, 500:415–21

802	38. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, Boot A,
803	Covington KR, Gordenin DA, Bergstrom EN, Islam SMA, Lopez-Bigas N, Klimczak LJ,
804	McPherson JR, Morganella S, Sabarinathan R, Wheeler DA, Mustonen V, Getz G, Rozen
805	SG, Stratton MR. The repertoire of mutational signatures in human cancer. Nature, 2020,
806	578:94–101
807	39. Georgeson P, Pope BJ, Rosty C, Clendenning M, Mahmood K, Joo JE, Walker R,
808	Hutchinson RA, Preston S, Como J, Joseland S, Win AK, Macrae FA, Hopper JL, Mouradov
809	D, Gibbs P, Sieber OM, O'Sullivan DE, Brenner DR, Gallinger S, Jenkins MA, Winship IM
810	Buchanan DD. Evaluating the utility of tumour mutational signatures for identifying
811	hereditary colorectal cancer and polyposis syndrome carriers. Gut, 2021, 70:2138-49
812	40. Georgeson P, Harrison TA, Pope BJ, Zaidi SH, Qu C, Steinfelder RS, Lin Y, Joo JE,
813	Mahmood K, Clendenning M, Walker R, Amitay EL, Berndt SI, Brenner H, Campbell PT,
814	Cao Y, Chan AT, Chang-Claude J, Doheny KF, Drew DA, Figueiredo JC, French AJ,
815	Gallinger S, Giannakis M, Giles GG, Gsur A, Gunter MJ, Hoffmeister M, Hsu L, Huang W-
816	Y, Limburg P, Manson JE, Moreno V, Nassir R, Nowak JA, et al. Identifying colorectal
817	cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures.
818	Nat Commun, 2022, 13:3254
819	41. Jenkins MA, Win AK, Templeton AS, Angelakos MS, Buchanan DD, Cotterchio M,
820	Figueiredo JC, Thibodeau SN, Baron JA, Potter JD, Hopper JL, Casey G, Gallinger S, Le
821	Marchand L, Lindor NM, Newcomb PA, Haile RW, Colon Cancer Family Registry Cohort I
822	Cohort Profile: The Colon Cancer Family Registry Cohort (CCFRC). Int J Epidemiol, 2018,
823	47:387–388i

824	42.	Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, Hall D, Hopper JL,
825		Jass J, Le Marchand L, Limburg P, Lindor N, Potter JD, Templeton AS, Thibodeau S,
826		Seminara D, Colon Cancer Family R. Colon Cancer Family Registry: an international
827		resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol
828		Biomarkers Prev, 2007, 16:2331–43
829	43.	Buchanan DD, Clendenning M, Rosty C, Eriksen SV, Walsh MD, Walters RJ, Thibodeau
830		SN, Stewart J, Preston S, Win AK, Flander L, Ouakrim DA, Macrae FA, Boussioutas A,
831		Winship IM, Giles GG, Hopper JL, Southey MC, English D, Jenkins MA. Tumour testing to
832		identify Lynch syndrome in two Australian colorectal cancer cohorts. J Gastroenterol
833		Hepatol, 2017, 32:427–38
834	44.	Walsh MD, Buchanan DD, Pearson S-A, Clendenning M, Jenkins MA, Win AK, Walters RJ,
835		Spring KJ, Nagler B, Pavluk E, Arnold ST, Goldblatt J, George J, Suthers GK, Phillips K,
836		Hopper JL, Jass JR, Baron JA, Ahnen DJ, Thibodeau SN, Lindor N, Parry S, Walker NI,
837		Rosty C, Young JP. Immunohistochemical testing of conventional adenomas for loss of
838		expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series
839		from the Australasian site of the colon cancer family registry. Mod Pathol, 2012, 25:722–30
840	45.	Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper JL, Jenkins MA, Young J, Buchanan
841		D, Walsh MD, Le Marchand L, Burnett T, Newcomb PA, Grady WM, Haile RW, Casey G,
842		Plummer SJ, Krumroy LA, Baron JA, Thibodeau SN. Quality assessment and correlation of
843		microsatellite instability and immunohistochemical markers among population- and clinic-
844		based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn, 2011,
845		13:271-81

846	46. Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST,
847	Thompson BA, Lose FA, Parsons MT, Walters RJ, Pearson SA, Cummings M, Oehler MK,
848	Blomfield PB, Quinn MA, Kirk JA, Stewart CJ, Obermair A, Young JP, Webb PM, Spurdle
849	AB. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of
850	patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for
851	population-level germline mismatch repair gene mutation testing. J Clin Oncol, 2014, 32:90-
852	100
853	47. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH,
854	Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine
855	J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW. CpG island methylator
856	phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF
857	mutation in colorectal cancer. Nat Genet, 2006, 38:787-93
858	48. Zaidi SH, Harrison TA, Phipps AI, Steinfelder R, Trinh QM, Qu C, Banbury BL, Georgeson
859	P, Grasso CS, Giannakis M, Adams JB, Alwers E, Amitay EL, Barfield RT, Berndt SI,
860	Borozan I, Brenner H, Brezina S, Buchanan DD, Cao Y, Chan AT, Chang-Claude J,
861	Connolly CM, Drew DA, Farris AB, Figueiredo JC, French AJ, Fuchs CS, Garraway LA,
862	Gruber S, Guinter MA, Hamilton SR, Harlid S, Heisler LE, Hidaka A, et al. Landscape of
863	somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nat
864	Commun, 2020, 11:3644
865	49. Belhadj S, Terradas M, Munoz-Torres PM, Aiza G, Navarro M, Capellá G, Valle L.
866	Candidate genes for hereditary colorectal cancer: Mutational screening and systematic
867	review. Hum Mutat, 2020, 41:1563–76

868	50.	Seifert BA, McGlaughon JL, Jackson SA, Ritter DI, Roberts ME, Schmidt RJ, Thompson
869		BA, Jimenez S, Trapp M, Lee K, Plon SE, Offit K, Stadler ZK, Zhang L, Greenblatt MS,
870		Ferber MJ. Determining the clinical validity of hereditary colorectal cancer and polyposis
871		susceptibility genes using the Clinical Genome Resource Clinical Validity Framework.
872		Genet Med, 2019, 21:1507–16
873	51.	Weren RDA, Ligtenberg MJL, Kets CM, de Voer RM, Verwiel ETP, Spruijt L, van Zelst-
874		Stams WAG, Jongmans MC, Gilissen C, Hehir-Kwa JY, Hoischen A, Shendure J, Boyle EA,
875		Kamping EJ, Nagtegaal ID, Tops BBJ, Nagengast FM, Geurts van Kessel A, van Krieken
876		JHJM, Kuiper RP, Hoogerbrugge N. A germline homozygous mutation in the base-excision
877		repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet, 2015,
878		47:668–71
879	52.	Spurdle AB, Bowman MA, Shamsani J, Kirk J. Endometrial cancer gene panels: clinical
880		diagnostic vs research germline DNA testing. Mod Pathol, 2017, 30:1048-68
881	53.	Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R,
882		Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L,
883		Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic
884		characterization of endometrial carcinoma. Nature, 2013, 497:67-73
885	54.	Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow
886		RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB, Akbani R,
887		Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bodenheimer T,
888		Bogomolniy F, Boice L, Bootwalla MS, Bowen J, Bowlby R, Broaddus R, Brooks D,
889		Carlsen R, Cherniack AD, Cho J, Chuah E, Chudamani S, et al. Integrated Molecular
890		Characterization of Uterine Carcinosarcoma. Cancer Cell, 2017, 31:411-23

- 891 55. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence
 892 data. Bioinformatics, 2014, 30:2114–20
- 893 56. Saunders CT, Wong WSW, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate
- somatic small-variant calling from sequenced tumor–normal sample pairs. Bioinformatics,
- 895 2012, 28:1811–7
- 896 57. Sha D, Jin Z, Budzcies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor Mutational Burden
- 897 (TMB) as a Predictive Biomarker in Solid Tumors. Cancer Discov, 2020, 10:1808–25
- 58. Kuhn M, cre, Wing J, Weston S, Williams A, Keefer C, Engelhardt A, Cooper T, Mayer Z,
- 899 Kenkel B, R Core Team, Benesty M, Lescarbeau R, Ziem A, Scrucca L, Tang Y, Candan C,
- 900 Hunt T. caret: Classification and Regression Training. 2022
- 901 59. Tibshirani R. Regression Shrinkage and Selection via the Lasso. Journal of the Royal
- 902 Statistical Society Series B (Methodological), 1996, 58:267–88
- 903 60. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, Grolemund G,
- Hayes A, Henry L, Hester J, Kuhn M, Pedersen TL, Miller E, Bache SM, Müller K, Ooms J,
- 905 Robinson D, Seidel DP, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H.
- 906 Welcome to the Tidyverse. Journal of Open Source Software, 2019, 4:1686
- 907 61. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M. pROC: an
- 908 open-source package for R and S+ to analyze and compare ROC curves. BMC
- 909 Bioinformatics, 2011, 12:77
- 910 62. LeDell E, Petersen M, Laan M van der. cvAUC: Cross-Validated Area Under the ROC
- 911 Curve Confidence Intervals. 2022
- 912 63. Friedman JH, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models
- 913 via Coordinate Descent. Journal of Statistical Software, 2010, 33:1–22

- 914 64. Thiele C, Hirschfeld G. cutpointr: Improved Estimation and Validation of Optimal Cutpoints
- 915 in R. Journal of Statistical Software, 2021, 98:1–27
- 916 65. Wickham H. The Split-Apply-Combine Strategy for Data Analysis. Journal of Statistical
- 917 Software, 2011, 40:1–29
- 918 66. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2016
- 919 67. Rudis B, cre, Kennedy P, Reiner P, support) DW (Secondary axis, Adam X, Fonts) G
- 920 (Roboto C& TW, Font) I (Plex S, Font) IT (Public S, Barnett J, Leeper TJ, Meys J.
- hrbrthemes: Additional Themes, Theme Components and Utilities for "ggplot2." 2020
- 922 68. Slowikowski K, Schep A, Hughes S, Dang TK, Lukauskas S, Irisson J-O, Kamvar ZN, Ryan
- 923 T, Christophe D, Hiroaki Y, Gramme P, Abdol AM, Barrett M, Cannoodt R, Krassowski M,
- 924 Chirico M, Aphalo P. ggrepel: Automatically Position Non-Overlapping Text Labels with
- 925 "ggplot2." 2021
- 926 69. Clopper CJ, Pearson ES. THE USE OF CONFIDENCE OR FIDUCIAL LIMITS
- 927 ILLUSTRATED IN THE CASE OF THE BINOMIAL. Biometrika, 1934, 26:404–13
- 928 70. Dorai-Raj S. binom: Binomial Confidence Intervals for Several Parameterizations. 2022
- 929 71. Renault V, Tubacher E, How-Kit A. Assessment of Microsatellite Instability from Next-
- 930 Generation Sequencing Data. Edited by Laganà A. Computational Methods for Precision
- 931 Oncology, Cham, Springer International Publishing, 2022, pp. 75–100
- 932 72. Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite Instability
- 933 Detection by Next Generation Sequencing. Clinical Chemistry, 2014, 60:1192–9
- 934 73. Ratovomanana T, Cohen R, Svrcek M, Renaud F, Cervera P, Siret A, Letourneur Q, Buhard
- 935 O, Bourgoin P, Guillerm E, Dorard C, Nicolle R, Ayadi M, Touat M, Bielle F, Sanson M,
- 936 Rouzic PL, Buisine M-P, Piessen G, Collura A, Fléjou J-F, Reyniès A de, Coulet F,

007	O1 · · 1 11 · F	· 1/m	T 1 \ T7	D 14		CAT	\sim \cdot	a ·
937	(thiringhelli H	Andre I	Ionchere V	Duval A	Performance	ot Nevt.	(ieneration	Sequencing
151	Ommignom i a	finale 1,	, Jonenere v	, Duvai 11.	1 UIIUIIIIIIIIIU	J OI I WAL	Ocheration	Sequeneing

- 938 for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA
- 939 Mismatch Repair. Gastroenterology, 2021, 161:814-826.e7
- 940 74. Roufas C, Georgakopoulos-Soares I, Zaravinos A. Molecular correlates of immune cytolytic
- subgroups in colorectal cancer by integrated genomics analysis. NAR Cancer, 2021,
- 942 3:zcab005
- 943 75. Zaravinos A, Roufas C, Nagara M, de Lucas Moreno B, Oblovatskaya M, Efstathiades C,
- 944 Dimopoulos C, Ayiomamitis GD. Cytolytic activity correlates with the mutational burden
- 945 and deregulated expression of immune checkpoints in colorectal cancer. J Exp Clin Cancer
- 946 Res, 2019, 38:364
- 947 76. Chen W, Pearlman R, Hampel H, Pritchard CC, Markow M, Arnold C, Knight D, Frankel
- 948 WL. MSH6 immunohistochemical heterogeneity in colorectal cancer: comparative
- sequencing from different tumor areas. Hum Pathol, 2020, 96:104–11

951 Figures





Analysis 2. Assessment of A) individual tumor features, B) statistical model and C) additive feature combination approaches derived from the WES analysis on panel sequenced CRCs, ECs and SSTs

			dMMR N = 51	pMMR N = 20	
				C) Additive feature combination Model	Mean Accuracy
A) Individu	ual feature	B) Statis	tical model	≥3/6 of MSMuTect + MANTIS + MSIseq	
MANTIS	Mean Accuracy	<u>Lasso</u>	Mean Accuracy	+ MSISensor + INDEL count + TMS ID2+ID7	
CRC	100.0%	CRC	89.7%	CRC	100.0%
EC	86.4%	EC	68.2%	EC	95.5%
SST	85.0%	SST	85.0%	SST	100.0%

953 Figure 1. Overview of the study design. In total, 300 whole-exome sequenced (WES) colorectal 954 cancers (CRCs) consisting of 91 DNA mismatch repair deficient (dMMR) and 209 DNA mismatch 955 repair proficient (pMMR) tumors were analyzed. We investigated 104 tumor features for their 956 ability to distinguish dMMR from pMMR tumors consisting of four MSI tools, 97 tumor 957 mutational signature definitions (TMS), tumor mutation burden (TMB) calculated as mutations 958 per mega base, somatic insertion / deletion (INDEL) and somatic single nucleotide variant (SNV) 959 counts. We performed a 10-fold cross-validation approach with 100 repeats to calculate the mean 960 accuracy on the test dataset. (A) The top 10 ranked individual tumor features, (B) a Lasso 961 regression model and (C) an additive feature combination approach was tested to determine the 962 benefit of combining tumor features to improve dMMR prediction. The findings from these three 963 approaches were tested on an independent set of targeted panel sequenced tumors of CRC, 964 endometrial cancer (EC) and sebaceous skin tumor (SST) tissue types with reported mean 965 accuracies.



Figure 2. Tumor distribution of the top 10 DNA mismatch repair (MMR) deficient (dMMR) predicting features in the whole exome
sequenced (WES) colorectal cancers (CRCs) by MMR subtype. Boxplots showing the distribution of tumors by MMR status (MMRproficient (pMMR) versus dMMR) as well as stratified by dMMR subtype - dMMR-LS (Lynch syndrome), dMMR-DS (double somatic
MMR gene mutations) and dMMR-MLH1me (*MLH1* promoter methylation) for each of the top 10 predicting features MSMuTect,
MANTIS, MSISensor, MSIseq, INDEL (insertion / deletion) count, TMB (tumor mutation burden calculated as mutations / mega base),
TMS (tumor mutational signature) ID2+ID7, TMS SBS15, TMS SBS20 and TMS SBS54 as determined from the WES CRC analysis.

973 ID, small insertions / deletions; SBS, single base substitution.



975 Figure 3. Determination of thresholds for differentiating DNA mismatch repair (MMR) deficient (dMMR) from MMR-proficient 976 (pMMR) colorectal cancers (CRCs) using whole exome sequencing (WES) data for each of the top 10 performing tumor features. Bar 977 graphs presenting the distribution of tumors after applying the recommended thresholds (red line) for each of the top 10 predicting tumor 978 features MSMuTect, MANTIS, MSISensor, MSIseq, INDEL count, TMB, TMS ID2+ID7, TMS SBS15, TMS SBS20 and TMS SBS54 979 as determined from the WES CRC analysis. Orange coloring indicates pMMR and blue coloring represents dMMR status. ID, small 980 insertions / deletions; SBS, single base substitution.



Feature Counting by MMR Status for WES Tumors

Figure 4. The additive tumor feature combination approach demonstrating the distribution of counts of the top six tumor features by the DNA mismatch repair (MMR) status of the 300 colorectal cancers (CRCs) with whole exome sequencing (WES). Bar graphs presenting the distribution of tumors after applying the additive tumor feature combination approach with the recommended thresholds from the WES CRC analysis using a count of \geq 3 out of the top six predictors from the WES CRC analysis, consisting of MSMuTect, MANTIS, MSIseq, MSISensor, INDEL (insertion / deletion) count and TMS (tumor mutational signature) ID2+ID7 (small insertions / deletions) for MMR status calling: MMR-deficient (dMMR) versus MMR-proficient (pMMR).

988 Tables

989	Table 1. The breakdown of the	104 tumor features	calculated from next	generation seq	uencing analy	sis included in this stud	٩t.
				0 1			~

Feature Type	Count	Name	Reference
Total	N = 104		
Microsatellite instability (MSI) Tools	N = 4	MSISensor	Niu et al., 2014
		MSIseq	Huang et al., 2015
		MANTIS	Kautto et al., 2017
		MSMuTect	Maruvka et al., 2017
Tumor mutational signatures (TMS)	N = 97	SBS (N = 78)	Tate <i>et al.</i> , 2018
		ID (N = 18)	Tate et al., 2018
		ID2+ID7	Georgeson et al., 2021
Somatic mutation counts	N = 3	INDELs	
		SNVs	
		TMB (SNVs + INDELs/ MB)	Muzny et al., 2012

The 104 tumor features can be categorized into three distinct groups: microsatellite instability (MSI) tools, tumor mutational signatures (TMS) and somatic mutation counts. These features have previously been shown to be associated with MSI / DNA mismatch repair status as indicated by the provided references. The MSI group consists of four MSI tools namely MSISensor, MSIseq, MANTIS and MSMuTect. TMS consisted of 78 single base substitutions (SBS), 18 small insertions / deletions (IDs) and TMS ID2+ID7. The somatic 994 mutation count consisted of the single nucleotide variant count, larger insertions / deletions count and the tumor mutation burden (TMB),

995 which was calculated as the combination of SNVs and INDELs counts per megabase.

Table 2. Performance of the top tumor features demonstrating a prediction accuracy >80% ranked by highest mean accuracy from

Tumor	Mean	Error	95% CI	: Mean	95% CI:	Mean	95% CI:	Mean AUC	95% CI:
Feature	Accura	Rate	(Accuracy)	Sensitivi	(Sensitivity)	Specificity	(Specifity)		(AUC)
	cy			ty					
MSMuTect	99.3%	0.7%	99.1%	- 97.6%	96.9% -	100.0%	-	98.8%	98.5% - 99.1%
			99.5%		98.3%				
MSIseq	99.1%	0.9%	98.9%	- 97.7%	97.0% -	99.8%	99.6% -	98.7%	98.4% - 99.1%
			99.4%		98.3%		100.0%		
MANTIS	99.0%	1.0%	98.8%	- 97.1%	96.4% -	99.9%	99.8% -	98.5%	98.1% - 98.8%
			99.2%		97.7%		100.0%		
INDEL count	98.9%	1.1%	98.7%	- 97.7%	97.0% -	99.5%	99.2% -	98.6%	98.2% - 98.9%
			99.2%		98.3%		99.8%		
MSISensor	97.7%	2.3%	97.3%	- 93.4%	92.4% -	99.5%	99.3% -	96.5%	96.0% - 97.0%
			98.0%		94.5%		99.7%		
TMS	96.8%	3.2%	96.4%	- 94.2%	93.2% -	97.9%	97.5% -	96.0%	95.5% - 96.6%
ID2+ID7			97.2%		95.2%		98.4%		

998 whole-exome sequenced (WES) colorectal cancers (CRCs).

TMS ID2	93.3%	6.7%	92.8% -	90.7%	89.5% -	94.4%	93.7% -	92.6%	92.0% - 93.1%
			93.8%		91.9%		95.1%		
TMS SBS20	88.4%	11.6	87.6% -	68.9%	66.6% -	97.0%	96.4% -	82.9%	81.8% - 84.1%
		%	89.2%		71.2%		97.6%		
TMS ID7	87.6%	12.4	87.0% -	74.2%	72.6% -	93.5%	92.8% -	83.9%	83.0% - 84.7%
		%	88.3%		75.9%		94.2%		
TMS SBS54	83.4%	16.6	82.6% -	59.4%	57.5% -	93.9%	93.1% -	76.7%	75.6% - 77.7%
		%	84.2%		61.4%		94.7%		
TMB	83.3%	16.7	82.6% -	57.8%	55.2% -	94.5%	93.7% -	76.1%	75.0% - 77.3%
		%	83.9%		60.4%		95.2%		
TMS SBS15	82.4%	17.6	81.5% -	58.8%	56.5% -	92.8%	91.9% -	75.8%	74.6% - 77.0%
		%	83.3%		61.1%		93.7%		

999 The mean accuracy values after 10-fold cross-validation with 100 repeats, error rate, mean sensitivity, mean specificity, and mean area 1000 under the curves (AUCs) with corresponding 95% confidence intervals (CIs) are shown for each of the top 10 predicting tumor features 1001 MSMuTect, MSIseq, MANTIS, INDEL (insertion / deletion) count, MSISensor, TMS (tumor mutational signature) ID2+ID7, TMS 1002 ID2, TMS SBS20, TMS ID7, TMS SBS54, TMB (tumor mutation burden) and TMS SBS15 from the WES CRC analysis. ID, small 1003 insertions, and deletions; SBS, single base substitutions.

Table 3. Summary of the best dMMR prediction results by individual tumor feature, Lasso regression model and the additive feature
 combination approach for the whole-exome sequencing (WES) colorectal cancers (CRCs) and the panel sequenced CRCs, endometrial
 cancers (ECs) and sebaceous skin tumors (SST).

	Performance of best Individual Feature		Performance of Statistical Mod	lel	Performance of Additive Feature Combination Approach			
WES	Feature Mean		Lasso	Mean	Feature Combination	Mean		
		Accuracy		Accuracy		Accuracy		
CRC	MSMuTect	99.3%	MANTIS + TMS ID2+ID7 +	98.3%	MSMuTect + MANTIS + MSIseq +	99.7%		
			MSISensor + TMS SBS15		MSISensor + INDEL count + TMS ID2+ID7			
PANEL	Feature	Accuracy	Lasso	Accuracy	Feature Combination	Accuracy		
CRC	MANTIS	100.0%	MANTIS + TMS ID2+ID7 +	89.7%	MSMuTect + MANTIS + MSIseq +	100.0%		
			MSISensor + TMS SBS15		MSISensor + INDEL count + TMS ID2+ID7			
EC	MANTIS	86.4%	MANTIS + TMS ID2+ID7 +	68.2%	MSMuTect + MANTIS + MSIseq +	95.5%		
			MSISensor + TMS SBS15		MSISensor + INDEL count + TMS ID2+ID7			
SST	MANTIS	85.0%	MANTIS + TMS ID2+ID7 +	85.0%	MSMuTect + MANTIS + MSIseq +	100.0%		
			MSISensor + TMS SBS15		MSISensor + INDEL count + TMS ID2+ID7			

- 1008 This table provides the top performing results from A) individual tumor feature, B) statistical model application (Lasso) and C) additive
- 1009 feature combination approach assessments for WES CRCs as well as targeted panel sequenced CRCs, ECs and SSTs.
- 1010 TMS, tumor mutational signature; ID, small insertions, and deletions; SBS, single base substitution; INDEL count, insertions / deletions.

	CRC			EC			SST		
Tumor	Mean	95% CI	Error	Mean	95% CI	Error	Mean	95% CI	Error
Feature	Accuracy		Rate	Accuracy		Rate	Accuracy		Rate
MSMuTect	27.6%	12.7% - 47.2%	72.4%	18.2%	5.2% - 40.3%	81.8%	35.0%	15.4% -	65.0%
								59.2%	
MSIseq	82.8%	64.2% - 94.2%	17.2%	68.2%	45.1%	31.8%	65.0%	40.8% -	35.0%
					86.1%			84.6%	
MANTIS	100.0%	88.1% -	0.0%	86.4%	65.1% -	13.6%	85.0%	62.1% -	15.0%
		100.0%			97.1%			96.8%	
INDEL count	27.6%	12.7% - 47.2%	72.4%	18.2%	5.2% - 40.3%	81.8%	35.0%	15.4% -	65.0%
								59.2%	
MSISensor	96.6%	82.2% - 99.9%	3.4%	77.3%	54.6% -	22.7%	75.0%	50.9% -	25.0%
					92.2%			91.3%	
TMS	82.8%	64.2% - 94.2%	17.2%	63.6%	40.7% -	36.4%	85.0%	62.1% -	15.0%
ID2+ID7					82.8%			96.8%	

Table 4. Assessment of top performing tumor features from whole-exome sequenced (WES) colorectal cancers (CRCs) in panel

1013 sequenced CRC, endometrial cancer (EC) and sebaceous skin tumor (SST) test sets.

TMS SBS20	69.0%	49.2% - 84.7%	31.0%	50.0%	28.2% -	50.0%	40.0%	19.1% -	60.0%
					71.8%			63.9%	
TMS SBS54	51.7%	32.5% - 70.6%	48.3%	36.4%	17.2% -	63.6%	40.0%	19.1% -	60.0%
					59.3%			63.9%	
TMB	44.8%	26.4% - 64.3%	55.2%	31.8%	13.9% -	68.2%	35.0%	15.4% -	65.0%
					54.9%			59.2%	
TMS SBS15	44.8%	26.4% - 64.3%	55.2%	27.3%	10.7% -	72.7%	60.0%	36.1% -	40.0%
					50.2%			80.9%	

Table presents the prediction accuracies, error rates and corresponding 95% confidence intervals (CIs) for panel sequenced CRCs, ECs and SSTs for the top 10 predicting tumor features MSMuTect, MSIseq, MANTIS, INDEL (insertions / deletions count), MSISensor, TMS (tumor mutational signature) ID2+ID7, TMS SBS20, TMS SBS54, TMB (tumor mutation burden, mutations / mega base) and TMS SBS15 from WES CRC analysis applied on panel sequenced CRCs, ECs and SSTs. ID, small insertions, and deletions; SBS, single

1018 base substitution.